Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRN110755 in EGFR-mutant non-small cell lung cancer
2025-523122-40-00Phase 2Authorised
- Sponsor
- Voronoi
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, open-label trial of VRN110755 in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Voronoi. Primary endpoints: Dose-limiting toxicities and safety, Phase 2 efficacy and 1 more. Planned start Oct 2026; status: authorised.
02
Drugs
VRN110755
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-523122-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523122-40-00.